drugset / Trial / NCT04652115
Defibrotide for the Treatment of Severe COVID-19
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2026-12-24
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Defibrotide | Oligonucleotide (other) | 6.25 mg/kg | Intravenous |
| Subject | Defibrotide | Oligonucleotide (other) | 10 mg/kg | Intravenous |